Cargando…
The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study
BACKGROUND: Preoperative chemotherapy (PCT) has become the standard of care in locally advanced breast cancer. The identification of patient-specific tumor characteristics that can improve the ability to predict response to therapy would help optimize treatment, improve treatment outcomes, and avoid...
Autores principales: | Wang, Linbo, Jiang, Zhinong, Sui, Meihua, Shen, Jianguo, Xu, Chaoyang, Fan, Weimin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716368/ https://www.ncbi.nlm.nih.gov/pubmed/19591668 http://dx.doi.org/10.1186/1471-2407-9-226 |
Ejemplares similares
-
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study
por: Dong, Minjun, et al.
Publicado: (2018) -
The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells
por: Jiang, Zhinong, et al.
Publicado: (2012) -
FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014) -
Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression
por: Huang, Yuan, et al.
Publicado: (2017) -
Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer
por: Zhou, Jichun, et al.
Publicado: (2016)